Home » FDA Says Resources, Staffing Delayed a PDUFA Deadline
FDA Says Resources, Staffing Delayed a PDUFA Deadline
The FDA delayed another deadline under the Prescription Drug User Fee Act (PDUFA), this time for Takeda Pharmaceutical. Takeda, whose PDUFA date for its NDA for alogliptin (SYR-332) to treat Type 2 diabetes was delayed in October, learned late December that the action date had been postponed again, this time until June 26.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May